This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

3 Stocks Dragging In The Health Care Sector

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average (^DJI) trading down 42 points (-0.3%) at 15,847 as of Thursday, Dec. 5, 2013, 11:45 AM ET. The NYSE advances/declines ratio sits at 971 issues advancing vs. 1,916 declining with 131 unchanged.

The Health Care sector currently sits down 0.3% versus the S&P 500, which is down 0.4%. On the negative front, top decliners within the sector include Cigna (CI), down 1.4%, HCA Holdings (HCA), down 1.0%, UnitedHealth Group (UNH), down 0.9%, WellPoint (WLP), down 0.7% and Biogen Idec (BIIB), down 0.5%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Alkermes (ALKS) is one of the companies pushing the Health Care sector lower today. As of noon trading, Alkermes is down $1.20 (-2.9%) to $39.80 on average volume. Thus far, 373,309 shares of Alkermes exchanged hands as compared to its average daily volume of 841,900 shares. The stock has ranged in price between $39.45-$40.28 after having opened the day at $39.69 as compared to the previous trading day's close of $41.00.

Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. Alkermes has a market cap of $5.6 billion and is part of the drugs industry. The company has a P/E ratio of 293.7, above the S&P 500 P/E ratio of 17.7. Shares are up 121.4% year to date as of the close of trading on Wednesday. Currently there are 5 analysts that rate Alkermes a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Alkermes as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall. Get the full Alkermes Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs